Latest Company Funding News

Etherstack plc has successfully raised $6.1 million through an institutional placement, positioning the company to fast-track its Home project and enhance its MCPTX IWF technology.

Regal Partners Limited reported a robust 13.1% increase in funds under management to $20 billion, driven by strong client inflows and positive investment returns. Performance fees for the second half of 2025 are tracking well above broker expectations, signaling strong momentum.

Equity Story Group Ltd has voluntarily suspended trading of its shares pending a forthcoming announcement about a capital raise, signaling a significant funding event.

Boom Logistics has confirmed the resignation of former CEO Ben Pieyre following investigations into his unauthorised use of company funds, with losses estimated under $1 million and ongoing inquiries underway.

Dubber Corporation Limited reported a 9% increase in revenue to $42.19 million for FY25, alongside a significant reduction in net loss. However, challenges remain with a major contract non-renewal and ongoing efforts to recover $26.6 million in misused funds.

Earlypay Ltd reported a 31% rise in statutory net profit after tax for FY25, driven by growth in equipment finance despite declines in invoice and trade finance. The company declared a fully franked final dividend of 0.65 cents per share and outlined plans to expand its lending portfolios and streamline technology.

LGI Limited reported a robust FY25 with 14% EBITDA growth driven by expanded renewable energy capacity and carbon credit sales, while setting ambitious FY26 guidance of 25-30% EBITDA growth.

Traka Resources has announced a $2.5 million capital raise through a two-tranche placement, alongside significant board and executive changes that could reshape its strategic direction.

Clime Investment Management has reported a solid operating profit for the June quarter, declared a fully franked dividend, and announced strategic expansions in staff and product offerings.

Regal Partners Limited reported a 7% increase in funds under management to $17.7 billion for the June quarter, driven by strong inflows and investment gains. The company also upgraded its performance fee and profit forecasts for the first half of 2025.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

Regal Partners estimates at least $35 million in performance fee revenue for the first half of 2025, driven by strong global equity strategies and diverse alternative funds. The full half-year results will be released on 25 August.